Home » Stocks » INZY

Inozyme Pharma, Inc. (INZY)

Stock Price: $16.15 USD 0.15 (0.94%)
Updated May 11, 2021 4:00 PM EDT - Market closed
Market Cap 373.23M
Revenue (ttm) n/a
Net Income (ttm) -56.42M
Shares Out 23.47M
EPS (ttm) -5.11
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 11
Last Price $16.15
Previous Close $16.00
Change ($) 0.15
Change (%) 0.94%
Day's Open 15.90
Day's Range 15.42 - 16.22
Day's Volume 24,787
52-Week Range 15.42 - 31.65

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Results presented at the European Calcified Tissue Society Congress provide first evidence of increased plasma pyrophosphate (PPi) levels and reduced calcification with an enzyme replacement therapy in ...

4 days ago - GlobeNewsWire

- Peer-reviewed article in Journal of Bone and Mineral Research showed INZ-701 increased pyrophosphate (PPi) levels, improved disease markers, and decreased mortality in an ENPP1-deficient mouse model -

1 week ago - GlobeNewsWire

BOSTON, April 28, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization disord...

1 week ago - GlobeNewsWire

- Study results underscore high and shifting disease impacts across age groups, reflecting evolution of disease symptomology - - Study results underscore high and shifting disease impacts across age gro...

3 weeks ago - GlobeNewsWire

BOSTON, April 08, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases of abnormal mi...

1 month ago - GlobeNewsWire

- Appoints veteran leaders with deep scientific and clinical expertise in vascular calcification, renal disease, and diseases with neointimal proliferation - - Appoints veteran leaders with deep scienti...

1 month ago - GlobeNewsWire

– Received Orphan Drug Designation by the U.S. Food and Drug Administration for INZ-701 for treatment of ABCC6 deficiency –

1 month ago - GlobeNewsWire

Educational Episode to Highlight Symptoms of ENPP1 Deficiency and the Importance of Early Diagnosis  Educational Episode to Highlight Symptoms of ENPP1 Deficiency and the Importance of Early Diagnosis

2 months ago - GlobeNewsWire

BOSTON, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases of abnormal min...

3 months ago - GlobeNewsWire

– U.S. Food and Drug Administration cleared Investigational New Drug Application –

4 months ago - GlobeNewsWire

–  Submitted CTA for INZ-701 for the treatment of ENPP1 deficiency to United Kingdom regulatory agency –

5 months ago - GlobeNewsWire

Dr. Johnson Brings More Than 25 Years of Experience in Developing and Implementing Global Regulatory and Clinical Development Strategies from Preclinical Through Product Approval Dr. Johnson Brings More...

6 months ago - GlobeNewsWire

– Dr. Sabbagh Brings More Than 20 Years of Experience in Rare Genetic Disorders and Mineral Metabolism Research Development Programs –

6 months ago - GlobeNewsWire

Upsized IPO in July 2020 raised $128.8 million in gross proceeds

8 months ago - GlobeNewsWire

About INZY

Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquarter... [Read more...]

Industry
Biotechnology
IPO Date
Jul 24, 2020
Stock Exchange
NASDAQ
Ticker Symbol
INZY
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for Inozyme Pharma stock is "Strong Buy." The 12-month stock price forecast is 36.67, which is an increase of 127.06% from the latest price.

Price Target
$36.67
(127.06% upside)
Analyst Consensus: Strong Buy